GNX1021 is GlycoNex's lead glycan-targeted antibody-drug conjugate (ADC) candidate, developed to treat advanced gastrointestinal cancers including gastric, colorectal, and pancreatic carcinomas. The drug targets branched Lewis B/Y (bLeB/Y), a tumor-associated carbohydrate antigen (TACA) overexpressed on epithelial tumor cells and minimally expressed on healthy human tissue. This selectivity profile underpins the candidate's therapeutic-window potential. In April 2026, Japan's Pharmaceuticals and Medical Devices Agency (PMDA) cleared GNX1021 for first-in-human Phase 1 clinical trials, and patient enrollment in Japan is scheduled to begin in June 2026. A parallel Investigational New Drug (IND) submission to Taiwan's regulatory authority is planned in the same month. GNX1021 is built on GlycoNex's proprietary GlycoSH antibody library — one of the most extensive collections of anti-glycan monoclonal antibodies, developed over more than two decades of dedicated glycobiology research at GlycoNex's New Taipei City laboratories.
GNX1021
Glycan-Targeted ADC for Gastrointestinal Cancers
Overview
Mechanism of Action
Antibody recognizes bLeB/Y
Antibody binds branched Lewis B/Y glycan on tumor cell surface
Receptor-mediated internalization
ADC enters cell via endocytosis
Lysosomal cleavage
Linker is cleaved inside lysosome
Payload release
Cytotoxic payload released into cytoplasm
Tumor cell death
DNA damage triggers apoptosis
Most clinical-stage ADCs target protein antigens — HER2, TROP2, Claudin-18.2 — and consequently compete in increasingly crowded indication spaces. GNX1021 instead targets a tumor-associated carbohydrate antigen, exploiting the aberrant glycosylation patterns that distinguish many epithelial cancers from healthy tissue.
Because branched Lewis B/Y is expressed across multiple GI tumor types and is largely independent of HER2 status, GNX1021 has the potential to address HER2-negative patient segments and reach a broader population than any single protein-target ADC.
Indications & Market Opportunity
Gastric Cancer
HER2-negative gastric cancers face limited targeted-therapy options after first-line failure — a clear unmet need for glycan-targeted modalities.
Colorectal Cancer
Refractory mCRC after standard chemotherapy + targeted regimens has 5-year survival under 15%; new ADC targets are urgently needed.
Pancreatic Cancer
Among the deadliest solid tumors, pancreatic adenocarcinoma has minimal viable targeted-therapy options — a classic high-unmet-need ADC opportunity.
bLeB/Y is overexpressed across all three indications, allowing GNX1021 to be developed as a coordinated GI-cancer franchise rather than three siloed programs.
Development Status
-
Discovery & preclinical development
Lead-candidate selection, in vivo efficacy, IND-enabling toxicology and CMC.
-
Preclinical data presented at AACR 2025
Tumor-selective expression and in vivo efficacy disclosed at the American Association for Cancer Research annual meeting.
-
Preclinical data published
Detailed mechanistic and efficacy data released via PR Newswire.
-
Japan PMDA Phase 1 clearance Milestone
PMDA authorizes first-in-human dosing in patients with advanced gastrointestinal cancers.
-
Taiwan IND submission planned
Parallel filing with Taiwan FDA to enable a multi-regional Phase 1 footprint.
-
First patient dosing in Japan (planned)
Phase 1 site activation at lead investigator hospital.
-
Phase 1 readout expected
Initial safety, PK, and signal-of-efficacy data.
Why GNX1021 Stands Out
Glycan target advantage
Targets a tumor-associated carbohydrate antigen rather than a protein, broadening tumor coverage and avoiding redundant competition with HER2 / TROP2 / Claudin-18.2 ADCs.
20+ years of glycan antibody science
Drawn from the GlycoSH antibody library, built since GlycoNex's founding in 2001 in collaboration with the late Dr. Sen-itiroh Hakomori (US National Academy of Sciences).
Validated by Japan PMDA
One of the few Taiwan-originated ADCs to clear PMDA review for first-in-human studies, signaling regulatory confidence in the candidate's preclinical package.
Vertically integrated manufacturing
Internal 200L GMP facility supplies clinical material, eliminating CDMO dependency for early-phase supply and protecting timeline integrity.
References
- AACR 2025 Poster — available on request
- PR Newswire — (preclinical data release)
- PR Newswire — (Japan PMDA Phase 1 clearance)
- Taiwan TWSE Material Information Disclosure — TWSE 4168
Partner with us on GNX1021
GlycoNex is actively engaging global pharmaceutical partners on GNX1021 — including out-licensing, regional licensing (ex-Japan), and co-development structures. We welcome discussions with companies whose oncology pipeline aligns with novel glycan-targeted modalities.